Prurigo Nodularis Clinical Trials

8 recruiting

Prurigo Nodularis Trials at a Glance

10 actively recruiting trials for prurigo nodularis are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 3 with 5 trials, with the heaviest enrollment activity in Mainz, Miami, and Coral Gables. Lead sponsors running prurigo nodularis studies include Incyte Corporation, Sanofi, and Guangdong Hengrui Pharmaceutical Co., Ltd.

Browse prurigo nodularis trials by phase

Treatments under study

About Prurigo Nodularis Clinical Trials

Looking for clinical trials for Prurigo Nodularis? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prurigo Nodularis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prurigo Nodularis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2Phase 3

Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis

Prurigo Nodularis
Guangdong Hengrui Pharmaceutical Co., Ltd423 enrolled1 locationNCT06554509
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

Prurigo Nodularis
Incyte Corporation330 enrolled120 locationsNCT06516952
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

Prurigo Nodularis
Incyte Corporation330 enrolled119 locationsNCT06516965
Recruiting
Phase 2

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.135 enrolled16 locationsNCT07236099
Recruiting

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Prurigo Nodularis
Galderma R&D600 enrolled51 locationsNCT06988618
Recruiting
Phase 3

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

Prurigo Nodularis
Sanofi18 enrolled14 locationsNCT06293053
Recruiting

Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

Prurigo Nodularis (PN)
UMC Utrecht40 enrolled1 locationNCT07276425
Recruiting

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

Prurigo Nodularis
Sanofi150 enrolled11 locationsNCT06087627
Recruiting
Phase 3

Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis

Prurigo Nodularis
Shanghai Mabgeek Biotech.Co.Ltd160 enrolled1 locationNCT06779136
Recruiting
Phase 4

Upadacitinib for Prurigo Nodularis

Prurigo Nodularis
Psoriasis Treatment Center of Central New Jersey25 enrolled1 locationNCT06773403